--Citigroup Adjusts Price Target on Beam Therapeutics to $60 From $62, Keeps Buy Rating

--Citigroup Adjusts Price Target on Beam Therapeutics to $60 From $62, Keeps Buy Rating

MT Newswires · 05/11/2023 04:37

Please log in to view news